

# *In silico* and *in vivo* anti-stress potential of *Stachytarpheta cayennensis* (Verbenaceae) in mice

ItunuOluwa M. Akanmu<sup>1</sup>, Lateef A. Akinpelu<sup>2\*</sup>, A. Aliyu<sup>3</sup>, Moses A. Akanmu<sup>4</sup>

<sup>1</sup>Department of Pharmacology and Toxicology, College of Pharmacy, Igbinedion University, Okada, Edo State, Nigeria.

<sup>2</sup>Department of Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, University of Ilorin, Ilorin, Kwara State, Nigeria.

<sup>3</sup>Department of Pharmaceutical Microbiology & Biotechnology, Faculty of Pharmaceutical Sciences, University of Ilorin, Ilorin, Kwara State, Nigeria.

<sup>4</sup>Department of Pharmacology, Faculty of Pharmacy, Obafemi Awolowo University, Ile Ife, Osun State, Nigeria.

## ARTICLE INFO

### Article history:

Received 25th September 2024  
Revised 11th October 2024  
Accepted 18th October 2024  
Online  
Published

### Keywords:

*Stachytarpheta cayennensis*,  
betulinic acid,  
*in vivo* studies,  
*in silico* studies,  
antistress potential

### \*Corresponding Author:

Akinpelu Lateef Abiola  
Email: [akinpelu.la@unilorin.edu.ng](mailto:akinpelu.la@unilorin.edu.ng);  
[akinpelu\\_abiola01@yahoo.com](mailto:akinpelu_abiola01@yahoo.com)  
Tel: +2348038590621

## ABSTRACT

**Background:** *Stachytarpheta cayennensis* is locally used as an antistress agent but no scientific rationale for its use. Hence, this study evaluated the antistress potential of ethanol leaf extract of *Stachytarpheta cayennensis* (ELSC) in mice.

**Methods:** The stress induced anxiety was assessed using elevated plus maze following acute restraint stress in mice. The *in silico* studies of previously reported compounds from *Stachytarpheta cayennensis* (*S. cayennensis*) were also carried out.

**Results and discussion:** There was significant ( $p < 0.001$ ) increase in anxiety status of stressed control mice compared to the unstressed control suggesting stress induction. However, ELSC stressed at 125 and 250 mg/kg and diazepam stressed control significantly ( $p < 0.001$ ) reduced the anxiety indices of mice compared to the stressed control group suggesting the reversal of stress-induced anxiety in mice. The results of *in silico* studies revealed betulinic acid was the most favourable compound in terms of pharmacokinetics, toxicity profile and binding affinity. The post docking analysis showed that betulinic acid and the positive antistress drug (diazepam) interacted with amino acid residues of the target receptor protein active pockets. Moreso, betulinic acid has a stronger binding affinity (-7.8 Kcal/Mol) compared to diazepam (-6.9 Kcal/Mol), suggesting that betulinic acid may be a more effective antistress agent than diazepam.

**Conclusion:** This study therefore, concluded that betulinic acid may at least in part be responsible for the observed antistress effect of *Stachytarpheta cayennensis*. However, further studies may be carried out on the antistress potential of betulinic acid.

## Introduction

Stress is defined as a state of threatened or perceived threatened homeostasis caused by intrinsic or extrinsic stressors<sup>1</sup>. This threatened state of homeostasis is counteracted by the body complex neuroendocrine system known as 'stress system' which is made up of hypothalamic-pituitary-adrenal axis and the locus caeruleus/norepinephrine autonomic nervous systems<sup>2</sup>. The 'stress system' allows the body to deal effectively with

the stressor and re-establish homeostasis<sup>2</sup>. Abberations in proper stress response system may lead to several pathological conditions<sup>2</sup>.

The present-day life styles of high physical and psychological demands have made man prone to stress-related disorders such as anxiety, depression, insomnia<sup>3,4</sup>, cognitive impairment<sup>5,6</sup>, cardiovascular disorders<sup>7</sup> and psychosis<sup>8</sup>. Lack of gainful employment, divorce, child delivery, environmental pollution including wars constitute

common stressful events in life<sup>9,10</sup>. The consequence of body responding to stress includes hormonal imbalances, immune disorders and an increased incidence of cardiovascular disease<sup>11</sup>.

Several synthetic drugs such as benzodiazepine anxiolytics have been developed to manage stress but these drugs have failed in its utilisation against stress induced negative impacts on cognition, immunity, hypertension and peptic ulcer as well as its teratogenic effects on the unborn babies and deleterious effects on suckling infants<sup>12,13</sup>. Hence, the needs for new effective anti-stress agents to mitigate stress-induced disorders particularly from medicinal plants becomes pertinent and imperative<sup>14</sup>.

For many centuries ago, people of the ancient days have used plants to alleviate symptoms of illnesses and promote healing<sup>15</sup>. Plant-based medicines still play a pivotal role in many traditional and modern medical practices<sup>15</sup>. To this effect, many medicinal plants have been evaluated for their antistress potentials<sup>16,17</sup>. However, *Stachytarpheta cayennensis* leaf has not been evaluated for its antistress potential despite its use for combating stress in traditional settings (verbal communication)

The plant *Stachytarpheta cayennensis* (Rich.) Vahl, popularly known as verbena, belongs to the family

Verbenaceae<sup>18</sup>. This species is perennial herb native to America and distributed in tropical and subtropical parts of America, Brazil, Asia, and Australia and also found in other countries of the world such as Africa, Mexico and many more<sup>19,20</sup>. It is an erect, perennial, branching, somewhat angular, fibrous subshrub that is very resistant to traction<sup>21</sup>. The plant is traditionally employed to treat inflammation, pain, fever, cough, arthritis, malaria, gastric, liver and mental disorders, to induce sleep and for its diuretic and laxative potentials<sup>22-26</sup>.

Experimental findings have shown that *Stachytarpheta cayennensis* has anthelmintic<sup>27</sup>, anti-inflammatory<sup>28</sup>, antinociceptive<sup>29</sup>, antioxidant<sup>21</sup> anti-ulcerogenic<sup>30</sup>, antidiabetic<sup>31</sup>, antimalarial<sup>32</sup>, anti-diarrhoea activities<sup>33</sup>, sedative<sup>34</sup> and anxiolytic effects<sup>35</sup>. The presence of therapeutic phytochemicals such as alkaloids, tannins, steroids, terpenoids, saponins, phenols and flavonoids, quinones, glycosides, phenolic compounds and gluconic acid have been reported<sup>23,36</sup>.

The goal of this study is to provide scientific basis for the traditional use of *Stachytarpheta cayennensis* leaves in the treatment of stress.



**Plate 1: Picture of *Stachytarpheta cayennensis* in its natural habitat**

**Source: Obtained from the Obafemi Awolowo University campus in Ile-Ife, Osun State.**

---

## Materials and methods

### Collection of Plant Materials

*Stachytarpheta cayennensis* leaves were identified and collected from the wild on the campus of Obafemi Awolowo University (OAU) Ile-Ife, Nigeria during the month of August 2023. Herbarium voucher (FHI-106491) for *S. cayennensis* has been deposited with the National Herbarium, Forestry Research Institute of Nigeria, Ibadan.

### Preparation and extraction of plant materials

The plant leaves were subjected to fourteen (14) days of air drying in the laboratory at room temperature. The dried leaves were pulverized and 122 g of the powdered leaves was extracted by maceration with 1.5 litres of seventy percent (70%) ethanol solution for 72 hours. The marc was re-extracted twice. The extract was concentrated in a water bath at a set temperature of 40°C and subsequently freeze-dried to yield 13.22 g (10.84%) crude ethanol extract (ELSC). The crude extract was freshly prepared by dissolving in normal saline on each day of experiment.

### Animals

The animals used for the experiment were adult swiss albino mice of both sexes ( $21 \pm 1$  g). The animals were bred having free access to drinking water and standard commercial diet (Guinea feeds brand, Bendel Feeds, Nigeria), housed in the well aerated and lit animal house situated at the Central Animal House, Igbinedion University, Okada, Edo State. The mice were maintained under natural daylight and night condition. The studies were carried out between the hours of 9:00 am to 3:00 pm.

### Drug

Diazepam (Roche, Basel, Switzerland) and normal saline (Unique Pharmaceutical Limited, Lagos, Nigeria). Drugs and ELSC were dissolved and made up to the required concentration with normal saline on each day of the experiment.

### Acute toxicity test

The guideline described by the Organization for Economic Co-operation and Development (OECD) Annex 2 Test Guideline 42537 was used to determine the oral acute toxicity using a limit test at 2000 mg/kg p.o. as single dose for the extract. Mouse were kept without food for 3–4 h prior to dosing but had free access to water. A dose of 2000 mg/kg b.w was orally administered to one female mouse and closely observed for 30 mins and then 4 hr. Upon the


survival of the mouse, 4 additional female mice were orally administered the same dose of the drug and observed as done for the first mouse. The same procedure was followed for control group of 5 mice which were administered normal saline. All the mice were thereafter monitored in the morning and evening of each day for 14 consecutive days.

### Experimental Design

The adult mice were divided into 6 experimental groups (n=5). Group-1 mice (control unstressed) received normal saline (10 mL/kg p.o.) without stress, Group-2 mice (control stressed) received normal saline (10 mL/kg p.o.) 1 hr prior to acute restraint stress (ARS), Group-3 mice (standard drug-treated unstressed) received diazepam (2 mg/kg p.o.) without stress, Group-4 mice (standard drug-treated stressed) received diazepam (2 mg/kg p.o.) 1hr prior to ARS, Group-5 mice (Dose 1 stressed) were treated with ELSC (125 mg/kg p.o.) 1hr prior to ARS, Group-6 (Dose 2 stressed) received ELSC (250 mg/kg p.o.) 1hr prior to ARS.

### Acute restraint stress (ARS) procedure

The acute restraint stress model employed in this investigation was modified from previous research<sup>17</sup>. The animals were divided into six groups as mentioned above. Stressed groups were administered normal saline or ELSC and subjected to stress 1 hour after. Diazepam (2 mg/kg p.o.) was administered 30 min post treatment; the mice were then subjected to stress. In the 1 h for control and ELSC or 30 minutes for diazepam period passed between the stress procedure and treatment groups, the animals were inserted inside the plexiglas mouse restrainers for 1 hour applying immobilization. This restrained all physical movement causing no pain in animal (Plate 2). The animals were deprived of food and water during the entire restraint period. After 1 hour, the animals were removed and immediately subjected to behavioral tests.



**Plate 2: Mice being subjected to acute restraint stress (ARS)**

#### **Assessment of novelty-induced rearing and locomotion in open field test**

The open field test model is used to observe the general motor activity and exploratory behavior of animal (novelty induced behavior)<sup>38</sup>. This model was adapted from previous work<sup>39</sup> to assess the stress-related behavior in mice on the basis of changes in the exploration, general locomotor activity and spontaneous activity. Each mouse was exposed to the open field test for 10 min in a dimly light room with the mice placed at the center of the open field and the number of rearing (frequency with which the mouse stood on its hind legs) and line crossings (locomotion which is the frequency with which the mouse crosses one of the grid lines with all four paws) noted.

#### **Elevated Plus Maze (EPM)**

This test was used to assess the behavioral changes as earlier reported<sup>40</sup> based on the rodent's innate fear of heights and open areas. The plus maze comprises of two open arms (30 x 5 x 0.25 cm) and two enclosed arms (30 x 5 x 15 cm) extending from a common central platform (5 x 5 cm) with identical arms opposite each other. Between each examination, the maze was cleaned with 70% alcohol to remove any remaining smell cues. Each trial was recorded for 6 minutes with the parameters of open arm and close

arm entries and time spent in open arm and close arm of EPM recorded. The anxiety index of each mouse was calculated using the percentage number of open arm entries (%OE) and percentage open arm duration (%OT) as previously done<sup>41</sup>.

#### **Retrieval of previously reported compounds from *S. cayennensis***

Sixty eight compounds from *S. cayennensis* were retrieved online from previously published data<sup>32,42-47</sup>.

#### **Preparation of target protein**

The receptor protein used in this study to evaluate the in silico antistress potentials of the bioactive components of *S. cayennensis* was gotten from previous study<sup>48</sup> and downloaded from protein data bank (PDB) (<https://www.rcsb.org/>). The downloaded target protein (Crystal structure of a human gamma-aminobutyric acid receptor, the GABA (A) R-beta3 homopentamer: PDB ID 4COF)<sup>48</sup> was prepared using Chimera 1.10.2 software. The water molecule and all non-standard residues were removed from the protein. Thereafter, the protein was optimised for docking using dockprep tools. Polar hydrogen atom and Gasteiger charges were added to the protein and saved in pdb format.

### Ligand preparation

The bioactive compounds retrieved from *S. cayennensis* were downloaded from PubChem database (<https://pubchem.ncbi.nlm.nih.gov/>) with their PubChem CID numbers and saved in SDF format. Diazepam, a positive antistress agent was also downloaded from PubChem database. These ligands were prepared using Open Babel integrated in PyRx49 to minimize their energy and translated to pdbqt format in readiness for molecular docking.

### Molecular docking of protein and ligands


Molecular docking simulations were carried out using Vina Wizard integrated in PyRx. Prepared protein and ligands were loaded into PyRx and converted to pdbqt. The compounds were docked into the binding sites/pockets of the target protein using Vina Wizard of Pyrex software<sup>50</sup>.

### Ligands for *in silico* pharmacokinetics and toxicity predictions


From the result of molecular binding, compounds with stronger binding affinity than the positive antistress drug

(diazepam) were used for the *in silico* pharmacokinetics and toxicity predictions.


The *in silico* pharmacokinetics studies were carried out using SwissADME (<https://www.swissadme.ch>) and ADMETlab ([admetmesh.scbdd.com](http://admetmesh.scbdd.com)) online servers<sup>51</sup>. The drug-likeness of these compounds were predicted using the Lipinski's rule of five<sup>52</sup>. The 2D structures of Leucosceptoside A (PubChem ID: 10394343), Isoacetoside (PubChem ID: 6476333), Betulinic acid (PubChem ID: 64971), Jionoside D (PubChem ID: 9895632), Verbascoside (PubChem ID: 5281800), Martinsoside (PubChem ID: 13989933) and Martynoside (PubChem ID: 5319292) were downloaded from PubChem database in structured data file (SDF) format. Their respective SMILES were used through swissADME (<http://www.swiss.adme.ch/>) and ADMETlab online servers (<https://admetlab3.scbdd.com/>) to evaluate physicochemical and pharmacokinetics properties as well as the drug likeness of these compounds<sup>51,53</sup>.




Leucosceptoside A




Isoacteoside (Isoverbascoside)




Betulinic acid




Jionoside D




Acetoside (Verbascoside)



Martinoside



Martynoside



Diazepam

**Plate 3: Chemical structure of some compounds from *S. cayennensis* plant and diazepam.** Source: Downloaded from PubChem database (<https://pubchem.ncbi.nlm.nih.gov/>)

### ***In silico* toxicity predictions**

The toxicity prediction was carried out using ProTox II web server (<http://tox.charite.de/protox3/>). The 2D chemical structures of the compounds were converted to their respective SMILES and inputted into the online server for toxicity prediction. The oral acute toxicity ( $LD_{50}$ ) of the compounds was predicted. The organ toxicity (hepatotoxicity, nephrotoxicity and neurotoxicity) and toxicological endpoints (carcinogenicity, immunotoxicity, cytotoxicity, and mutagenicity) were also predicted<sup>54,55</sup>.

### **Protein-ligand interactions analysis**

From the results of *in silico* pharmacokinetics prediction, compound (s) that did not violate the drug-likeness test (Lipinski's rule of five)<sup>52</sup> has/have their receptor-ligand-interactions analyzed using LigPlot+ software<sup>56</sup>.

### **Statistical Analysis**

The results obtained from the experiments were expressed as mean  $\pm$  SEM and statistically analyzed using one way ANOVA (Analysis of Variance) followed by Dunnett's post hoc analysis. GraphPad InStat® Biostatistics software

(GraphPad Software, Inc., La Jolla, USA) was used as statistical tool. All tests were carried out with the significance level set at  $p < 0.05$ ,  $p < 0.01$  and  $p < 0.001$  compared to the control or stress control.

### **Results**

#### **Acute toxicity studies**

Acute oral toxicity studies showed that all the treated mice survived beyond 14 days hence, no mortality was observed for up to the dose of 2000 mg/kg of ESC.


#### **Effect of ethanol leaf extract of *Stachytarpheta cayennensis* on novelty-induced rearing in mice**

The stress control significantly ( $p < 0.01$ ) increased novelty-induced rearing compared to the control. However, DZP stress and ELSC at 125 and 250 mg/kg significantly ( $p < 0.001$ ) reversed the stress induced rearing compared to the stress control mice (Figure 1A).

#### **Effect of ethanol leaf extract of *Stachytarpheta cayennensis* on novelty-induced locomotion in mice**

The stress control significantly ( $p < 0.01$ ) increased novelty-

induced locomotion compared to the control. However, DZP stress and ELSC at 125 mg/kg significantly ( $p < 0.001$ ) reversed the stress induced locomotion compared to stress control. Similarly, ELSC at 250 mg/kg significantly ( $p < 0.05$ ) reversed the stress induced increase in locomotion compared to the stress control mice (Figure 1B).



**Figure 1: Effect of ethanol leaf extract of *Stachytarpheta cayennensis* on rearing (A) and Locomotion (B) in mice.**

Control; Normal saline (10 mL/kg, p.o.), ELSC (mg/kg); ethanol leaf extract of *Stachytarpheta cayennensis*, DZP; diazepam, STR; stress. Each bar represents Mean  $\pm$  SEM,  $n=5$  (ANOVA; Dunnett's post hoc), ### $p < 0.001$  compared to control and \* $p < 0.05$  and \*\*\* $p < 0.001$  compared to stress control.

**Effect of ethanol leaf extract of *Stachytarpheta cayennensis* on percentage number of open arm entry in mice**

There was significant ( $p < 0.001$ ) reduction in the percentage number of open arm entry in stress control compared to control group. However, DZP stress and ELSC (250 mg/kg) significantly ( $p < 0.01$ ) reversed the stress induced reduction in the percentage number of open arm entry compared to control. Similarly, ELSC (125 mg/kg) significantly ( $p < 0.05$ ) reversed the stress induced reduction in the percentage number of open arm entry compared to control (Figure 2A).

**Effect of ethanol leaf extract of *Stachytarpheta cayennensis* on percentage number of open arm duration in mice.**


There was significant ( $p < 0.001$ ) reduction in the percentage number of open arm duration in stress control compared to control group. However, ELSC (125 mg/kg) and ELSC (250 mg/kg) significantly ( $p < 0.001$ ) and ( $p < 0.05$ ) reversed the stress induced reduction in the percentage number of open arm duration compared to control respectively. Similarly, DZP stress significantly ( $p < 0.05$ ) reversed the stress induced reduction in the percentage number of open arm duration compared to control (Figure 2B).

**Effect of ethanol leaf extract of *Stachytarpheta cayennensis* on percentage number of open arm duration in mice.**

The stress control significantly ( $p < 0.001$ ) increased the anxiety indices of mice compared to the control. However, DZP stress, ELSC at 125 mg/kg and 250 mg/kg significantly ( $p < 0.001$ ) ameliorated the increased anxiety indices induced by stress control in mice (Figure 2C).

induced  
the stres:  
stress inc

reversed  
ersed the



**Figure 2: Effect of ethanol leaf extract of *Stachytarpheta cayennensis* on percentage number of open arm entry (A), percentage number of open arm duration and antianxiety index (C) in mice.**

Control; Normal saline (10 mL/kg, p.o.), ELSC (mg/kg); ethanol leaf extract of *Stachytarpheta cayennensis*, DZP; diazepam, STR; stress. Each bar represents Mean  $\pm$  SEM, n=5 (ANOVA; Dunnett's post hoc), ###p<0.001 compared to control and \*p<0.05, \*\*p<0.01 and \*\*\*p<0.001 compared to stress control.



### Results of molecular docking

Of all the 68 compounds docked, Leucosceptoside A (-7.9 Kcal/Mol), Iso-acteoside (-7.8 Kcal/Mol), Betulinic acid (-7.8 Kcal/Mol), Jionoside (-7.5 Kcal/Mol), Verbascoside (-7.3 Kcal/Mol), Martinoside (-7.1 Kcal/Mol), Martynoside (-7.1 Kcal/Mol) have higher docking scores compared to the positive control drug diazepam (6.9 Kcal/Mol) on GABA<sub>A</sub> receptor site [Table 1].


The post docking analysis using LIGPLOT showed that diazepam and betulinic acid interacted with GABA<sub>A</sub> receptor protein at 8 common position that is TYR97, TYR157, PHE105, PHE98, ILE130, ASP101, VAL106, SER104, and THR106 amino acids residues [Figure 3].


**Table 1:** Binding affinity of retrieved compounds from *C. cayenensis* and diazepam at GABA<sub>A</sub> receptor site

Compound	PubChem CID	Docking scores (Kcal/Mol)	
		4COF	
1. Leucosceptoside A	10394343	-7.9	
2. Isoacteoside	6476333	-7.8	
3. Betulinic acid	64971	-7.8	
4. Jionoside D	9895632	-7.5	
5. Verbascoside	5281800	-7.3	
6. Martinoside	13989933	-7.2	
7. Martynoside	5319292	-7.1	
8. Diazepam	3016	-6.9	

Results of pharmacokinetics predictions of compounds from *S. cayennensis* using Swiss ADME

All the evaluated compounds (Leucosceptoside A, Isoacetoside, Betulinic acid, Jionoside, Verbascoside Martinoside and Martynoside) have low gastrointestinal (GIT) absorption values. All except betulinic acid (0.85) have bioavailability values of 0.17. Similarly, all except betulinic acid violated the Lipinski's rule of five for drug-likeness [Table 2].





### 4cof\_Betulinic\_acid\_Interaction

Figure 3: 2D representation of Diazepam (A) and Betulinic acid (B) showing interactions with different amino acid residues of 4COF receptor.

**Table 2: *In-silico* pharmacokinetics predictions of previously isolated compounds from *S. cayenensis***

Compounds	MW	GIT absorption	Bioavailability	T1/2	CLp	Drug-likeness	
A	638.61	Low		0.17	3.39	2.85	No
B	624.59	Low		0.17	3.11	4.51	No
C	456.7	Low		0.85	0.79	6.35	Yes
D	638.6	Low		0.17	3.55	2.63	No
E	624.6	Low		0.17	4.31	3.18	No
F	652.6	Low		0.17	3.83	2.86	No
G	652.6	Low		0.17	3.29	2.12	No

MW = Molecular weight in g/mol; T1/2 = Half life; CLp = plasma clearance; A = Leucosceptoside A; B = Isoacetoside; C = Betulinic acid; D = Jionoside D; Verbascoside; Martinoside; F = Martynoside

#### ***Results of toxicity predictions of compounds from S. stachytarpheta using ProTox II***

All the compounds evaluated except Jinoside showed to be inactive in hepatotoxicity, neurotoxicity except Jinoside in *in silico* toxicity predictions. However, 4 compounds (57.1%) were active for nephrotoxicity (Leucosceptoside A, Isoacetoside, Verbascoside, Martinoside and Martynoside), 1 compound (14.3%) was positive for carcinogenicity (Betulinic acid). All compounds were inactive for mutagenicity and cytotoxicity and all are active for immunotoxicity. All the evaluated compounds belong to toxicity class 5 except Jionoside that belongs to class 4 [Table 3].

**Table 3: *In silico* toxicity prediction of compounds previously isolated from *Stachytarpheta cayennensis***

Compounds	LD <sub>50</sub>	T-class	Organ toxicity				End point toxicity									
			Hepatotoxicity		Neurotoxicity		Nephrotoxicity		Carcinogenicity		Immunogenicity		Mutagenicity		Cytotoxicity	
			Toxicity	Prob	Toxicity	Prob	Toxicity	Prob	Toxicity	Prob	Toxicity	Prob	Toxicity	Prob	Toxicity	Prob
A	5000	5	Inactive	0.82	Inactive	0.86	Active	0.74	Inactive	0.82	Active	0.99	Inactive	0.88	Inactive	0.75
B	5000	5	Inactive	0.79	Inactive	0.89	Active	0.75	Inactive	0.82	Active	0.99	Inactive	0.86	Inactive	0.75
C	2610	5	Inactive	0.54	Inactive	0.79	Inactive	0.60	Active	0.53	Active	0.74	Inactive	0.74	Inactive	0.97
D	1190	4	Active	0.69	Active	0.87	Inactive	0.90	Inactive	0.62	Active	0.96	Inactive	0.97	Inactive	0.93
E	5000	5	Inactive	0.81	Inactive	0.87	Active	0.75	Inactive	0.81	Active	0.99	Inactive	0.87	Inactive	0.77
F	5000	5	Inactive	0.82	Inactive	0.86	Active	0.73	Inactive	0.81	Active	0.99	Inactive	0.86	Inactive	0.73
G	5000	5	Inactive	0.82	Inactive	0.86	Active	0.73	Inactive	0.81	Active	0.99	Inactive	0.86	Inactive	0.73

LD<sub>50</sub> = median lethal dose; T-class = toxicity class; Prob = probability; A = Leucosceptoside A; B = Isoacetoside; C = Betulinic acid; D = Jionoside; Verbascoside; Martinoside; F = Martynoside

### Discussion and conclusion

This study investigated the *in vivo* antistress potential of ethanol leaf extract of *Stachytarpheta cayennensis* (ELSC) using acute restraint stress (ARS) in mice. It went further to carry out *in silico* analyses (molecular docking, pharmacokinetics and toxicity predictions) using GABA<sub>A</sub> receptor site<sup>48</sup> and retrieved ligands previously reported to be present in *Stachytarpheta cayennensis*<sup>31,42-47</sup>.

In the oral acute toxicity test, no death that was observed up to 2000 mg/kg suggest that the extract may be safety margin of up to 2000 mg/kg in mice. Hence the extract may be considered to belong to a lower class of toxicity<sup>57</sup>. This *in vivo* acute toxicity finding may also be supported at least in part by the *in silico* toxicity prediction, which predicted toxicity class 5 (may be harmful if swallowed) for six out of the seven compounds and class 4 (harmful if swallowed) for the seventh compound from *S. cayennensis* subjected to *in silico* toxicity predictions in this study<sup>58</sup>. Based on the acute toxicity finding, lower doses of 125 and 250 mg/kg were used in this study.

The novelty-induced behaviours have been extensively used to study the gross effects of agents on the central nervous system (CNS)<sup>59</sup>. Agents that stimulates the CNS increase novelty-induced rearing, grooming and locomotion, while agents that decrease these parameters depress the CNS<sup>59</sup>. Therefore, the increase in rearing and locomotion by stress control suggest that stress induces CNS excitation. However, the reversal of the induced stress by ELSC suggested that the extract may possess anti-stress potential in mice. This assertion can further be corroborated by the reduction in these parameters by a standard anti-stress drug diazepam used as positive control drug in this experiment.

The acute restraint stress (ARS) is a broadly used behavioral model in studying the molecular basis of stress-related issues<sup>60</sup> such as anxiety and depression. Earlier report has also shown that quantification of anxiety states post ARS induction made the mice to experience a higher level of anxiety on elevated plus maze<sup>16,17,61</sup>. In this study, ARS induced anxiety-like behavior as observed by the reduction in the percentage number of open arm entries and percentage time spent on the open arms as well as increased anxiety index as recorded from the index of open arm avoidance. The reversal of anxiety induced by ARS by the ELSC suggests that the extract may have mitigating effect on stress induced anxiety in mice. This assertion is in conformity with earlier experimental findings that ARS induced anxiety-like behavior which could be ameliorated by therapeutic agents<sup>16,17,62</sup>. Although the mechanism of anti-stress effect of ESC on anxiety-like behavior on EPM was not delineated in the study but it could be suggested that ESC might be acting like an agonist as does diazepam through GABA<sub>A</sub>-benzodiazepine receptor-Cl-channel complex in the elicitation of its antistress effect. This is in consonance with the earlier suggested agonistic action of *Euphorbia hirta* involved in the depletion of stress-induced anxiety-like behavior via GABA<sub>A</sub>- benzodiazepine receptor-Cl<sub>2</sub> channel complex<sup>63</sup>.

Molecular docking (MD) is an essential procedure in drug discovery and rational drug design<sup>64</sup>. This is because MD predicts the binding orientation of small molecule drug candidates into their protein targets to predict the affinity and activity of small molecules<sup>64,65</sup>. The stronger binding affinities of leucosceptoside A, isoacetoside, betulinic acid, jionoside D, verbascoside, martinoside, martynoside with respect to the binding affinity of diazepam [Table 1] on GABA<sub>A</sub> receptor site suggest that these compounds may be

the promising compounds in *S. cayennensis* that is at least in part responsible for the antistress potentials of the plant in this study. However, pharmacokinetics study revealed betulinic acid as the only drug candidate of all the compounds screened using Linpiski's rule of five<sup>52</sup>. Likewise, betulinic acid has the most favourable toxicity profile compared to other compounds in *in silico* toxicity predictions [Table 3]. This finding of the safety profile of betulinic acid from our *in silico* toxicity predictions can be corroborated by the findings of Pisha *et al.*<sup>66</sup> who reported the safety of betulinic acid in the treatment athymic mice carrying human melanomas. However, of concern in our toxicity prediction in this study, is the carcinogenicity and immunotoxicity associated with betulinic acid. Hence, further study may be warranted to clear this contradictions. The favourable *in silico* pharmacokinetics properties of betulinic acid can also be supported by the report of Udeani *et al.*<sup>67</sup>. Since betulinic acid was the most favourable compound in terms of binding affinity, pharmacokinetics and toxicity profile, this compound was further analyzed for its ligand-protein interaction using LIGPLOT<sup>56,68</sup>.

The ligand-receptor interaction for diazepam and betulinic acid showed that betulinic acid occupied the same active pockets like diazepam in 4COF receptor as also depicted in PDBSUM. Moreover, betulinic acid has a stronger binding affinity than diazepam suggesting that betulinic acid may be a more promising antistress candidate than diazepam (a positive control drug).

Betulinic acid is one of the naturally occurring pentacyclic lupane-type triterpenoid which is usually isolated from birch trees but also found widely distributed in other medicinal plants<sup>69,70</sup>. The observed antistress potential of betulinic acid in this study, along with its neuroprotective effect in other brain disorders involving the GABA<sub>A</sub> receptor, such as epilepsy<sup>71</sup>, anxiety<sup>72</sup>, and insomnia<sup>73</sup>, may be at least partially explained by its previously reported anti-oxidant and anti-inflammatory<sup>74,75</sup> effect as well as its high ability to cross the blood-brain barrier from earlier *in silico* studies<sup>76</sup>. It will therefore be plausible to suggest that betulinic acid in *S. cayennensis* may at least in part be responsible for the earlier reported anxiolytic<sup>35</sup>, sedative-hypnotic<sup>34,35</sup> and anticonvulsant<sup>77</sup> effects of the plant.

### Conclusion

In conclusion, the ethanol leaf extract of *Stachytarpheta cayennensis* may have anti-stress effects against stress-induced anxiety in mice. The study further concluded that betulinic acid may be acting in additive or synergy with other phytochemicals present in the extract to elicit the

observed antistress potential and GABAergic system may be involved in the antistress effect.

### CONFLICT OF INTEREST

None declared

### References

1. Yaribeygi H, Panahi Y, Sahraei H, Johnston TP, Sahebkar A (2017) The impact of stress on body function: A review. *EXCLI Journal*. 16:1057-1072. doi: [10.17179/excli2017-480](https://doi.org/10.17179/excli2017-480)
2. [Nicolaides](https://doi.org/10.1159/000528065) NC, [Chrousos](https://doi.org/10.1159/000528065) GP (2013). Impact of stress on health in childhood and adolescence. *Hormone Research in Paediatrics* 96(1): 5–7. <https://doi.org/10.1159/000528065>
3. Baum A, Polsusny D (1999) Health Psychology: Mapping Biobehavioral Contributions to Health and Illness. *Annual Review of Psychology* 50:137-163. <https://doi.org/10.1146/annurev.psych.50.1.137>.
4. Khan S, Khan RA (2017). Chronic stress leads to anxiety and depression. *Annals of Psychiatry and Mental Health* 5(1): 1091.
5. Al-Shargie F, Taresh SM, Al-Ezzi A (2024) Mental stress and cognitive deficits management. *Brain Sciences* 14(4): 316. <https://doi.org/10.3390/brainsci14040316>
6. Shields GS, Sazma MA, McCullough AM, Yonelinas AP (2017) The effects of acute stress on episodic memory: A meta-analysis and integrative review. *Psychological Bulletin* 143(6): 636–675. doi: [10.1037/bul0000100](https://doi.org/10.1037/bul0000100)
7. Dimsdale JE (2008) Psychological Stress and Cardiovascular Disease. *Journal of the American College of Cardiology* 51: 1237–1246. doi: [10.1007/s11936-019-0724-5](https://doi.org/10.1007/s11936-019-0724-5)
8. Mondelli V (2014) From stress to psychosis: whom, how, when and why? *Epidemiology and Psychiatric Sciences* 23(3): 215-8. doi: [10.1017/S204579601400033X](https://doi.org/10.1017/S204579601400033X)
9. Lisman J, Buzsáki G, Eichenbaum H, Nadel L, Ranganath C, Redish AD (2017) Viewpoints: how the hippocampus contributes to memory, navigation and cognition. *Nature Neuroscience* 20(11): 1434-1447. doi: [10.1038/nn.4661](https://doi.org/10.1038/nn.4661)
10. Hammen C (2005) Stress and depression. *Annual Review in Clinical Psychology* 1:293-319. <https://doi.org/10.1146/annurev.clinpsy.1.102803.143938>

11. Greenberg N, Carr JA, Summers CH (2002) Causes and consequences of stress. *Integrative and Comparative Biology* 42(3): 508-516. doi: [10.1093/icb/42.3.508](https://doi.org/10.1093/icb/42.3.508)
12. Glaeske G, Hoffmann F (2011). Medikamente- psychotrope und andere Arzneimittel mit Missbrauchsund Abhängigkeitspotenzial. *Jahrbuch Sucht*. pp73-96.
13. Husain I, Zameer S, Madaan T, Minhaj A, Ahmad W, Iqbaal A, Ali A, Najmi AK (2019) Exploring the multifaceted neuroprotective actions of *Emblca officinalis* (Amla): A review. *Metabolic Brain Diseases*. 34: 957-65. doi: 10.1007/s11011-019-00400-9.
14. Habbu PV, Mahadevan KM, Kulkarni PV, Daulatsingh C, Veerapur VP and Shastry RA (2010) Adoptogenic and *in vitro* antioxidant activity of flavanoids and other fractions of *Argyrea speciosa* (Burm. F) Boj. in acute and chronic stress paradigms in rodents. *Indian Journal Experimental Biology* 48:53-60.
15. Chaachouay N, Zidane L (2024). Plant-derived natural products: A source for drug discovery and development. *Drugs Drug Candidates* 3:184-207. <https://doi.org/10.3390/ddc3010011>
16. Akinpelu LA, Aiyelero OM and Olayiwola G (2019). Ethanol leaf extract of *Milicia excelsa* mitigates anxiety and depressive-like behaviours induced by acute restraint stress in mice. *GSC Biological and Pharmaceutical Sciences* 6(2): 30-39. doi: 10.30574/gscbps.2019.6.2.0012
17. Aiyelero OM, Adeyemi IA., Akinpelu LA, Akanmu MA (2023) Anxiolytic and antistress potentials of ethanol stem-bark extract of *Milicia excelsa* (Moraceae) in mice. *Iranian Journal of Pharmaceutical Sciences* 19(1):68-78. <https://doi.org/10.22037/ijps.v19i1.43269>
18. Adedeji O (2010) Palynology of the genus *Stachytarpheta* Vahl. (Verbenaceae). *Notulae Scientia Biologicae* 2:27-33.
19. Yadav PD, Modi KP, Shah MB (2021) Phytochemistry, pharmacology, and botanical aspects of *Stachytarpheta* species –A review. *International Journal of Green Pharmacy* 15 (2): 114. <https://doi.org/10.22377/ijgp.v15i2.3078>
20. Alvarenga N, Olmedo DA, González-Maldonado P, Soto-Rifo R, Valiente-Echeverría F, Langjahr P, Sotelo PH (2024) Unraveling the antiviral activity of *Stachytarpheta cayennensis* against SARS-CoV-2 variants using *in vitro* and molecular docking analysis. *South African Journal of Botany* 69: 567-575. <https://doi.org/10.1016/j.sajb.2024.04.041>
21. Onofre SB, Santos ZMQ, Kagimura FY, Mattiello SP (2015) Antioxidant activity, total phenolic and flavonoids contents in *Stachytarpheta cayennensis*, (Rich.) Vahl. (Verbenaceae). *Journal of Medicinal Plant Research* 9(17):569-575.
22. Burkill, HM (1996). *Stachytarpheta cayennensis*. The Useful Plants of West Africa. *Royal Botanical Keids* 5: 268-9.
23. Hammer MLA, Johns EA (1993) Tapping and Amazonian plethora: four medicinal plants of Marajó Island, Pará-Brazil. *Journal of Ethnopharmacology* 40: 53 - 75. [https://doi.org/10.1016/0378-8741\(93\)90089-N](https://doi.org/10.1016/0378-8741(93)90089-N)
24. Schapoval EES, Winter DE, Vargas MR, Chaves CG, Raquel BJA, Zuanazzi ATH (1998) Anti-inflammatory and antinoceptive activities of extracts and isolated compounds from *Stachytarpheta cayennensis*. *Journal of Ethnopharmacology* 60(1): 53 - 59. [https://doi.org/10.1016/S0378-8741\(97\)00136-0](https://doi.org/10.1016/S0378-8741(97)00136-0)
25. Vela MS, Souccar C, Lima-Landman MT, Lapa AJ (2004) Pharmacological study of *Stachytarpheta cayennensis* Vahl in rodents. *Phytomedicine* 11:616-624. doi: 10.1016/j.phymed.2003.05.001.
26. Taylor L (2012) Raintree, tropical plant database. Milam County, Texas, USA.
27. Alice CB, Vargas VMF, Silva GAAB, De Siqueira NCS, Schapoval EES, Gleve J, Henriques JAP, Henriques AT (1991) Screening of plants used in South Brazilian folk medicine. *Journal of Ethnopharmacology* 35(2):165-171. [https://doi.org/10.1016/0378-8741\(91\)90069-P](https://doi.org/10.1016/0378-8741(91)90069-P)
28. Vela NS, Souccar C, Lima-Landman (1997) Inhibition of gastric acid secretion by three aqueous extracts and purified extracts of *Stachytarpheta cayennensis*. *Planta Medica* 63(1): 36-9. doi: 10.1055/s-2006-957599.
29. Penido C, Costa KA, Futuro DO, Paiva SR, Kaplan WA, Figueiredo MR, Henriques MG (2006) Anti-inflammatory and antiulcerogenic properties of *Stachytarpheta cayennensis* (L.C. Rich) Vahl. *Journal of Ethnopharmacology* 104:225-33. doi: [10.1016/j.jep.2005.09.006](https://doi.org/10.1016/j.jep.2005.09.006)

30. Almeida CE, Kamikowski MG, Foletto R, Baldisserotto B (1995) Analysis of the antidiarrhoeic effects of plants used in popular medicine. *Revista de Saude Publica* 29: 428-33. doi: 10.1590/s0034-89101995000600002.
31. Adebajo AC, Olawode EO, Omobuwajo OR, Adesanya SA, Begrow F, Elkhawad A, Akanmu MA, Edrada R, Proksch P, Schmidt TJ, Klaes M, Verspohl EJ (2007) Hypoglycaemic constituents of *Stachytarpheta cayennensis* leaf. *Planta Medica* 73(3): 241-50. doi:[10.1055/s-2007-967125](https://doi.org/10.1055/s-2007-967125)
32. Okokon JE, Etebong E, Antia BS (2008) *In vivo* antimalarial activity of ethanolic leaf extract of *Stachytarpheta cayennensis*. *Indian Journal of Pharmacology* 40: 111-113. doi: [10.4103/0253-7613.42303](https://doi.org/10.4103/0253-7613.42303)
33. Kvist LP., Christensen SB., Rasmusen HB., Mejia K. Gonzalez A (2006) Identification and evaluation of Peruvian plants used to treat malaria and leishmaniasis. *Journal of Ethnopharmacology* 106: 390-402. doi: 10.1016/j.jep.2006.01.020.
34. Akanmu MA, Olayiwola G, Ukponmwan OE, Honda K (2005) Acute toxicity and sleep-wake EEG analysis of *Stachytarpheta cayennensis* (Verbenaceae) in rodents. *African Journal of Traditional Complementary and Alternative Medicine* 2: 222-232.
35. Olayiwola G, Ukponmwan O, Olawode D (2013) Sedative and anxiolytic effects of the extracts of the leaves of *Stachytarpheta cayennensis* in mice *African Journal of Traditional Complementary and Alternative Medicine* 10(6):568-579. doi: 10.4314/ajtcam.v10i6.32.
36. Okoye TC, Akah PA, Okoli CO, Ezike AC, Mbaoji FN (2010) Antimicrobial and antispasmodic activity of leaf extract and fractions of *Stachytarpheta cayennensis*. *Asian Pacific Journal of Tropical Medicine* 3: 189-192. [https://doi.org/10.1016/S1995-7645\(10\)60006-5](https://doi.org/10.1016/S1995-7645(10)60006-5)
37. Hazarika I, Geetha KM, Sundrai PS, Madhu D (2019) Acute oral toxicity evaluation of extracts of *Hydrocotyle sibthorpiodes* in wistar albino rats as per OECD 425 TG. *Toxicological Report* 6: 321-328. doi: [10.1016/j.toxrep.2019.04.001](https://doi.org/10.1016/j.toxrep.2019.04.001)
38. Mechan AO, Moran PM, Elliot M, Young AJ, Joseph MH, Green RA (2022) Comparison between Dark Agouti and Sprague-Dawley rats in their behavior on the elevated plus-maze, open field apparatus and activity meters and their response to diazepam. *Psychopharmacology* 159:188-195. doi: 10.1007/s002130100902.
39. Sturman O, Germain PL, Bohacek J (2018) Exploratory rearing: a context- and stress-sensitive behavior recorded in the open-field test. *Stress* 21(5): 443-452. doi: 10.1080/10253890.2018.1438405.
40. Adebayo MA, Akinpelu LA, Okwuofu EO, Ibia DE, Lawson-Jack AF, Igbe I (2020) Anxiolytic, anti-amnesic and anticonvulsant activities of methanol leaf extract of *Bambusa vulgaris* (Poaceae) in mice. *Journal of African Association of Physiological Science* 8(2):149-157.
41. Akinpelu LA, Adebayo MA, Fajana A, Adeniyi-Akee MA, Ubogu SE, Aminu NS (2019). Phytochemical analyses, anxiolytic and anti-amnesic effect of methanol stem bark extract of *Vitex doniana* (Sweet) in mice. *Nigerian Journal of Natural Product and Medicine* 23:104-111.
42. Souza PAD, Silva CG, Machado BRP, de Lucas NM, Leitão GG, Eleutherio ECA, Ortiz GMD, Benchetrit LC. Evaluation of antimicrobial, antioxidant and phototoxic activities of extracts and isolated compounds from *Stachytarpheta cayennensis* (Rich.) Vahl, Verbenaceae. *Brazilian Journal of Pharmacognosy* 20(6):922-928. doi: [10.1590/S0102-695X2010005000042](https://doi.org/10.1590/S0102-695X2010005000042).
43. Ganapathy S, Shruthi SD, Lakshmikantha RY (2017). Antibacterial and molecular docking studies of bioactive component from leaves of *Stachytarpheta cayennensis* (Rich.) Vahl. *Research Journal of Phytochemistry* 11(1):28-34. doi: [10.3923/rjphyto.2016](https://doi.org/10.3923/rjphyto.2016)
44. Iwu IC, Onu UL, Ukaoma AA, Oze RN (2019). Phytochemical, antimicrobial and GC/MS analysis of the root of *Stachytarpheta cayennensis* (Vahl) grown in Eastern Nigeria. *International Research Journal of Nat Science* 7(2):20-32.
45. Otom OP, Okwute SK (2020). Chemical and biological screening of the leaves of *Stachytarpheta cayennensis* (Vahl). *International Journal of Research and Scientific Innovation* 6(12):61-67.
46. Yadav PD, Modi KP, Shah MB (2021). Phytochemistry, pharmacology, and botanical aspects of *Stachytarpheta* species – A

- review. *International Journal of Green Pharmacy* 15(2):114.  
<https://doi.org/10.22377/ijgp.v15i2.3078>
47. Oliveira TAS, Silva JBA, Barco JG, Groppo M, de Souza SL, Martins, CHG (2023) Chemical composition and antibacterial activity of the essential oil from *Stachytarpheta cayennensis* leaves grown in Brazil Southeast. *Journal of Essential Oil & Plant Composition* 1(2):32-38. doi:[10.58985/jeopc.2023.v01i02.06](https://doi.org/10.58985/jeopc.2023.v01i02.06)
48. Negi A, Singh P, Taneja N, Mani S (2018) Molecular-docking study of anti-stress natural compounds against GABAA Receptor portends the novel approach to stress treatment. *Journal of Applied Pharmaceutical Sciences* 8(12):038-043. doi:[10.7324/JAPS.2018.81205](https://doi.org/10.7324/JAPS.2018.81205)
49. Dallakyan S, Olson AJ (2015) Small-molecule library screening by docking with PyRx. *Methods in Molecular Biology* 1263:243-250. doi: 10.1007/978-1-4939-2269-7\_19.
50. Olubodun-Obadun TG, Ishola IO, Akinwande AS, Adeyemi OO (2023). *Cajanus cajan* (L) Millsp. seed extract ameliorates scopolamine-induced amnesia through increase in antioxidant defense mechanisms and cholinergic neurotransmission. *Nigerian Journal of Physiological Science* 38:91-99. doi: 10.54548/njps.v38i1.13.
51. Daina A, Michielin O, Zoete V (2017) SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. *Scientific Reports*. 7: 1-13. doi: 10.1038/srep42717.
52. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Advance Drug Delivery Review*. 46(1-3): 3-26. doi: 10.1016/s0169-409x(00)00129-0.
53. Rai M, Singh AV, Paudel N, Kanase A, Falletta E, Kerkar P, Heyda J, Barghash RF, Pratap SS, Soos M (2023). Herbal concoction unveiled: a computational analysis of phytochemicals' pharmacokinetic and toxicological profiles using novel approach methodologies (NAMs). *Current Research in Toxicology* 5: 100118. doi: [10.1016/j.crtox.2023.100118](https://doi.org/10.1016/j.crtox.2023.100118)
54. Banerjee P, Eckert AO, Schrey AK, Preissner R (2018) ProTox-II: a webserver for the prediction of toxicity of chemicals. *Nucleic Acids Research* 46:257-63. doi: [10.1093/nar/gky318](https://doi.org/10.1093/nar/gky318)
55. Drwa MN, Banerjee P, Dunkel M, Wettig MR, Preissner R (2014) ProTox: a web server for the in silico prediction of rodent oral toxicity. *Nucleic Acids Research* 42(1):53-8. doi: [10.1093/nar/gku401](https://doi.org/10.1093/nar/gku401)
56. Aliyu A, Ibrahim YKE, Tytler BA, Olowo-Okere A (2022) Antimicrobial peptide design, molecular docking and ADMET studies against the methicillin-resistant *Staphylococcus aureus* and carbapenem resistant and carbapenemase-producing *Pseudomonas aeruginosa*. *Trends Peptide Protein Science* 7:9. <https://doi.org/10.22037/tpps.v7i.39110>
57. Hazarika I, Geetha KM, Sundrai PS, Madhu D (2019) Acute oral toxicity evaluation of extracts of *Hydrocotyle sibthorpiodes* in wistar albino rats as per OECD 425 TG. *Toxicological Reports* 6: 321-328. <https://doi.org/10.22037/tpps.v7i.39110>
58. Winder C, Azzi R, Wagner D (2005) The development of the globally harmonized system (GHS) of classification and labelling of hazardous chemicals. *Journal of Hazardous Materials* 125(1-3):29-44. doi: 10.1016/j.jhazmat.2005.05.035.
59. Oyemitan IA, Bello OA, Akinpelu LA. (2015) Neuropharmacological evaluation of ethanolic leaf extract of *Alternanthera brasiliensis* (L.) Kuntze (Amaranthaceae) in mice. *International Journal of Pharmaceutical Science and Research* 6(9):3796-06. doi: 10.13040/IJPSR.0975-8232.6(9).3796-08
60. Duraisimi R, Mohite VA, Kasbe AJ (2010) Anti-stress, adaptogenic activity of standardized dried fruit extract of *Aegle marmelos* against diverse stressors. *Asian Journal of Pharmaceutical and Clinical Research* 2010;3(4): 1-3.
61. Raghu RA, Harsha SNS, Kumar DY, Neelima KSSN (2013) Effect of *Trichopus zeylanicus* leaf extract on acute stress induced anxiety in mice. *International Journal of Pharmaceutical Chemistry and Analysis* 1(7):445-449.
62. Sulakhiya K, Patel VK, Saxena R, Dashore J,

- Srivastava AK, Rathore M (2016) Effect of *Beta vulgaris* Linn. Leaves extract on anxiety- and depressive-like behavior and oxidative stress in mice after acute restraint stress. *Pharmacognosy Research* 8(1):1-7. doi: [10.4103/0974-8490.171100](https://doi.org/10.4103/0974-8490.171100)
63. Anuradha H, Srikumar BN, Rao BSS, Lakshmana M (2008). *Euphorbia hirta* reverses chronic stress-induced anxiety and mediates its action through the GABAA receptor benzodiazepine receptor-Cl<sub>2</sub> channel complex. *Journal of Neural Transmission* 115: 3542. doi: 10.1007/s00702-007-0821-6.
64. Pagadala NS, Syed K, Tuszynski J (2017) Software for molecular docking: A review. *Biophysical Reviews* 9: 91-102.
65. Utami JP, Diana S, Arifin R. (2022) *In silico* study of *Stachytarpheta jamaicensis* active compounds as antibacterial material. *Dentino Jurnal Kedokteran Gigi*. 7(1): 62-67.
66. Pisha E, Chai H, Lee IS, Chagwedera TE, Farnsworth NR, Cordell GA, Beecher CWW, Fong HHS, Kinghorn AD, Brown DM, Wani MC, Wall ME, Hieken TJ, Das Gupta TK, Pezzuto JM (1995) Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis. *Nature Medicine* 1:1046-1051. doi: 10.1038/nm1095-1046.
67. Udeani GO, Zhao GM, Geun Shin Y, Cooke BP, Graham J, Beecher CW, Kinghorn AD, Pezzuto JM (1999) Pharmacokinetics and tissue distribution of betulinic acid in CD-1 mice. *Biopharm Drug Dispos*. 20(8):379-83. doi: 10.1002/1099-081x(199911)20:8<379::aid-bdd198>3.0.co;2-c.
68. Laskowski RA, Swindells MB (2011) LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. *Journal of Chemical Information and Modeling* 51: 2778-2786. <https://doi.org/10.1021/ci200227u>
69. Moghaddam MG, Ahmad JBH, Samzadeh-Kermani A (2012) Biological activity of betulinic acid: A review. *Pharmacology and Pharmacy* 3:119-123. doi: [10.4236/pp.2012.32018](https://doi.org/10.4236/pp.2012.32018).
70. Ríos JL, Máñez S (2018) New pharmacological opportunities for betulinic acid. *Planta Medica* 84: 8-19. doi: [10.1055/s-0043-123472](https://doi.org/10.1055/s-0043-123472)
71. Muceniece R, Saleniece K, Rumaks J, Krigere L, Dzirkale Z, Mezhapuke R, Zharkova O, Klusa V (2008) Betulin binds to gamma-aminobutyric acid receptors and exerts anticonvulsant action in mice. *Pharmacology Biochemistry and Behaviour*. 90:712-716. doi: 10.1016/j.pbb.2008.05.015.
72. Puniani E, Cayer C, Kent P, Mullally M, Sánchez Vindas P, Álvarez LP, Cal V, Merali Z, Arnason JT, Durst T (2015) Ethnopharmacology of *Souroubea sympetala* and *Souroubea gilgii* (Marcgraviaceae) and identification of betulinic acid as an anxiolytic principle. *Phytochemistry* 113:73-78. doi: 10.1016/j.phytochem.2014.02.017.
73. Li B, Yang Y, Song Z, Tang Z (2024) Comparative analysis of the sedative and hypnotic effects among various parts of *Zizyphus spinosus* Hu and their chemical analysis. *Pharmaceuticals (Basel)*. 17(4):413. <https://doi.org/10.3390/ph17040413>
74. Osunsanmi FO, Zharare GE, Mosa RA, Ikhile MI, Shode FO, Opoku AR (2019) Anti-oxidant, anti-inflammatory and antiacetylcholinesterase activity of betulinic acid and 3β-acetoxymethylbetulinic acid from *Melaleuca bracteata* 'Revolution Gold'. *Tropical Journal of Pharmaceutical Research* 18(2): 303-309. doi: [10.4314/tjpr.v18i2.12](https://doi.org/10.4314/tjpr.v18i2.12)
75. Oliveira-Costa JF, Meira CS, Neves MVGD, Dos Reis BPZC, Soares MBP (2022). Anti-inflammatory activities of betulinic acid: A review. *Frontiers in Pharmacology* 13:883857. doi: [10.3389/fphar.2022.883857](https://doi.org/10.3389/fphar.2022.883857)
76. Khan MF, Nahar N, Rashid RB, Chowdhury A, Rashid MA (2018). Computational investigations of physicochemical, pharmacokinetic, toxicological properties and molecular docking of betulinic acid, a constituent of *Corypha taliera* (Roxb.) with Phospholipase A2 (PLA2). *BMC Complementary and Alternative Medicine* 18:48. doi: 10.1186/s12906-018-2116-x.
77. Okoye TC, Aguwa CN, Okoli CO, Akah PA, Nworu CS (2008) Anticonvulsant and sedative effects of leaf extracts of *Stachytarpheta cayennensis*. *Journal of Tropical Medicinal Plants* 9(1):17-22.